Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007041 · ClinicalTrials.gov registry record · Phase 4
Simultaneous RZV and aIIV4 Vaccination
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 267
- Enrollment target
NCT05007041 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 267 participants.
The verdict
NCT05007041, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 267 participants
- Enrollment target
Study Summary
The overall aim of the study is to compare the safety of simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®) versus simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Fluzone® High-Dose Quadrivalent vaccine in persons age ≥65 years. A prospective, randomized, blinded clinical trial that will be conducted during the 2021/2022 and 2022/2023 influenza seasons. Over the course of these two influenza seasons, approximately 220 older adults will be enrolled at Duke University Medical Center, and 180 older adults at Johns Hopkins University Medical Center. Eligible subjects will be randomized to receive either simultaneous RZV/FLUAD® or RZV/Fluzone® High-Dose vaccines. All subjects will be assessed for 7 days post-injection and safety and tolerability compared between the two groups. Serious adverse events and adverse events of clinical interest will be assessed 42 days post-vaccination and compared between the two groups. Health-related quality of life will be assessed pre-vaccination Day 1 through Day 8. Serious Adverse Events and Adverse Events of Clinical Interest were also assessed throughout the study period.
Interventions
- BIOLOGICAL FLUAD® Quadrivalent
- BIOLOGICAL Fluzone® High-Dose Quadrivalent
- BIOLOGICAL SHINGRIX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2021-09-21 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007041
The ClinicalTrials.gov registry entry for NCT05007041 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FLUAD® Quadrivalent is the first listed.
NCT05007041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05007041 about?
NCT05007041 is a clinical study titled "Simultaneous RZV and aIIV4 Vaccination". The overall aim of the study is to compare the safety of simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®) versus simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Fluzone® High-Dose Quadrivalent vacc...
What is the current status of trial NCT05007041?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 267 participants. The study started on 2021-09-21. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05007041?
The interventions under investigation include: FLUAD® Quadrivalent (BIOLOGICAL), Fluzone® High-Dose Quadrivalent (BIOLOGICAL), SHINGRIX® (BIOLOGICAL).
Who is sponsoring clinical trial NCT05007041?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.